All In Biotech

Drug Trial Radar · NCT07288320

An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder Who Are Currently Experiencing a Manic Episode or Manic Episode With Mixed Features, With or Without Psychotic Symptoms, and Warrant Inpatient Hospitalization

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Dec 24, 2025

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Dec 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving manic symptoms in adults with bipolar I disorder who are currently experiencing an episode of mania with or without mixed features.

Conditions

  • Bipolar I Disorder
  • Mania

Interventions

  • NBI-1117568Drug

    Oral administration

  • PlaceboDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Day 21Time frame: Baseline, Day 21

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Little Rock, Arkansas · Recruiting

  • Neurocrine Clinical Site

    Cerritos, California · Recruiting

  • Neurocrine Clinical Site

    Garden Grove, California · Recruiting

  • Neurocrine Clinical Site

    San Diego, California · Recruiting

  • Neurocrine Clinical Site

    Hollywood, Florida · Recruiting

  • Neurocrine Clinical Site

    Atlanta, Georgia · Recruiting

  • Neurocrine Clinical Site

    Gaithersburg, Maryland · Recruiting

  • Neurocrine Clinical Site

    Marlton, New Jersey · Recruiting

  • Neurocrine Clinical Site

    Staten Island, New York · Recruiting

  • Neurocrine Clinical Site

    Austin, Texas · Recruiting

  • Neurocrine Clinical Site

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.